Compare Ascendis Pharma A/S (ASND) vs Crowdstrike Holdings Inc (CRWD) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Crowdstrike Holdings Inc — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Crowdstrike Holdings Inc trades at $187.45 (market cap $190.60B). The key difference: Crowdstrike Holdings Inc is far larger — about 10.7× Ascendis Pharma A/S's market cap. Which is the better fit depends on your goals.
| ASND | CRWD | |
|---|---|---|
Market Cap | $17.74B | $190.60B |
Sector | Health | Technology |
52-Week High | $277.18 | $199.38 |
52-Week Low | $163.32 | $87.56 |
Enterprise Value | $18.11B | $186.87B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
CrowdStrike (CRWD) trades at $187.18, down 5.66% in the last session, following its recent 4-for-1 stock split. The stock exhibits a bullish technical trend with strong moving average signals, though RSI levels suggest overbought conditions. Fundamentally, the company shows robust revenue growth, reaching $3.95 billion in 2025, and has beaten earnings estimates for three consecutive quarters. However, valuation multiples remain elevated with a P/E of 765.02, and net income margins are negative. Analyst sentiment is overwhelmingly positive, with 76% recommending a buy.
The outlook for CRWD is supported by strong demand in AI-driven cybersecurity, but high valuation and intense competition pose risks. Revenue growth acceleration and market leadership in zero-trust security present opportunities, though profitability challenges and premium pricing require careful monitoring. The consensus price target of $184.40 suggests limited near-term upside from current levels, indicating a balanced risk-reward profile for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Crowdstrike Holdings Inc
CrowdStrike Holdings provides cybersecurity products and services aimed at protecting organizations from cyberthreats. It offers cloud-delivered protection across endpoints, cloud workloads, identity and data, and threat intelligence, managed security services, IT operations management, threat hunting, identity protection, and log management. CrowdStrike went public in 2019 and serves customers worldwide.
Read more on CRWD →
